| Autor: |
Behl T; Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India., Sharma A; Department of Pharmacology, School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh 173229, India., Sharma L; Department of Pharmacology, School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh 173229, India., Sehgal A; Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India., Singh S; Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India., Sharma N; Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India., Zengin G; Department of Biology, Faculty of Science, Selcuk University, Konya 42130, Turkey., Bungau S; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.; Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania., Toma MM; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.; Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania., Gitea D; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania., Babes EE; Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania., Judea Pusta CT; Department of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania., Bumbu AG; Department of Surgical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. |
| Abstrakt: |
Glioblastoma multiforme (GBM) is one of the debilitating brain tumors, being associated with extremely poor prognosis and short median patient survival. GBM is associated with complex pathogenesis with alterations in various cellular signaling events, that participate in cell proliferation and survival. The impairment in cellular redox pathways leads to tumorigenesis. The current standard pharmacological regimen available for glioblastomas, such as radiotherapy and surgical resection following treatment with chemotherapeutic drug temozolomide, remains fatal, due to drug resistance, metastasis and tumor recurrence. Thus, the demand for an effective therapeutic strategy for GBM remains elusive. Hopefully, novel products from natural compounds are suggested as possible solutions. They protect glial cells by reducing oxidative stress and neuroinflammation, inhibiting proliferation, inducing apoptosis, inhibiting pro-oncogene events and intensifying the potent anti-tumor therapies. Targeting aberrant cellular pathways in the amelioration of GBM could promote the development of new therapeutic options that improve patient quality of life and extend survival. Consequently, our review emphasizes several natural compounds in GBM treatment. We also assessed the potential of drug delivery techniques such as nanoparticles, Gliadel wafers and drug delivery using cellular carriers which could lead to a novel path for the obliteration of GBM. |
